Evidence map›Paper›PMID 37568681›Full record

ArticleCancers2023

Tumor and Nodal Disease Growth Rates in Patients with Oropharyngeal Squamous Cell Carcinoma.

Nicole I Farber, Yimin Li, Roberto N Solis, Joy Chen, Zahrah Masheeb, Machelle Wilson, Arnaud F Bewley, Marianne Abouyared, Shyam Rao, Yi Rong and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Nicole I FarberDepartment of Otolaryngology-Head and Neck Surgery, University of California Davis, Sacramento, CA 95817, USA.ORCID 0000-0003-1780-5780
Yimin LiDepartment of Radiation Oncology, University of California Davis, Sacramento, CA 94720, USA.
Roberto N SolisDepartment of Otolaryngology-Head and Neck Surgery, University of California Davis, Sacramento, CA 95817, USA.
Joy ChenDepartment of Otolaryngology-Head and Neck Surgery, University of California Davis, Sacramento, CA 95817, USA.
Zahrah MasheebDepartment of Otolaryngology-Head and Neck Surgery, University of California Davis, Sacramento, CA 95817, USA.
Machelle WilsonDavis-School of Medicine, University of California, Sacramento, CA 94720, USA.ORCID 0000-0003-1734-2755
Arnaud F BewleyDepartment of Otolaryngology-Head and Neck Surgery, University of California Davis, Sacramento, CA 95817, USA.
Marianne AbouyaredDepartment of Otolaryngology-Head and Neck Surgery, University of California Davis, Sacramento, CA 95817, USA.
Shyam RaoDepartment of Radiation Oncology, University of California Davis, Sacramento, CA 94720, USA.
Yi RongDepartment of Radiation Oncology, University of California Davis, Sacramento, CA 94720, USA.
Andrew C BirkelandDepartment of Otolaryngology-Head and Neck Surgery, University of California Davis, Sacramento, CA 95817, USA.
University of California, Davis · USFirst Affiliated Hospital of Xiamen University · CNMayo Clinic in Arizona · US

Funding

UC Davis Clinical and Translational Science CenterUL1TR001860 · NCATS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI KENYON, NICHOLAS J., LYLES, COURTNEY REES · 2016 to 2025
$47.3M
UC Davis Paul Calabresi K12 Clinical Oncology Research Career Development ProgramK12CA138464 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI BIRKELAND, ANDREW CHARLES, LARA, PRIMO N. · 2011 to 2025
$11.4M
NCATS NIH HHS UL1 TR001860NCI NIH HHS K12 CA138464
6 · The paper itself

Abstract

Though specific growth rate (SGR) has potential prognostic value for oropharyngeal squamous cell carcinoma (OPSCC), there is sparse literature defining these rates. Our aims were to establish the SGRs of primary tumors (PTs) and lymph nodes (LNs) in OPSCC and to correlate SGR with oncologic outcome. A pilot study was designed with a retrospective analysis examining 54 patients from the University of California, Davis with OPSCC (diagnosed 2012-2019). Radiation oncology software and pretreatment serial CT scans were used to measure PT and LN volumes to calculate SGR and doubling time (DT). The mean PT-SGR was 1.2 ± 2.2%/day and the mean LN-SGR was 1.6 ± 1.9%/day. There was no statistically significant difference between slow-growing and fast-growing cohorts in terms of age, gender, smoking status, tumor subsite, HPV status (as determined with p16 staining), initial volume, or overall stage. SGR had no impact on 2-year overall survival, disease-free survival, or disease-specific survival. We found the average daily growth rates for OPSCC to be 1.2%/day and 1.6%/day. Our findings suggest PT- and LN-SGR are independent factors, not heavily influenced by known biomarkers and patient characteristics, without a statistical impact on prognosis. This information has value in patient counseling regarding tumor growth and in providing patients worried about fast-growing tumors the appropriate reassurance.

Indexed as

oropharyngealsquamous cell carcinomatumor growth

Identifiers

PMID37568681
PMCPMC10416867
OpenAlexW4385400323

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.